ALKS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

378.57M

-11.96%

0.402

-61.72%

378.72M

+23.56%

0.380

+30.58%

473.70M

+21.26%

0.600

-11.6%

Estimates Revision

The market is revising Upward the revenue expectations for Alkermes plc (ALKS) for FY2025, with the revenue forecasts being adjusted by 3.43% over the past three months. During the same period, the stock price has changed by -4.97%.

Revenue Estimates for FY2025

Revise Upward

+3.43%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.51%

In Past 3 Month

Stock Price

Go Down

-4.97%

In Past 3 Month

16 Analyst Rating

Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 44.50 USD with a low forecast of 34.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

34.00

Averages

44.50

High

58.00

Current: 0.000

Low

34.00

Averages

44.50

High

58.00

Jefferies

Hold

downgrade

$23

2025-11-26

Reason

Jefferies

Price Target

$23

2025-11-26

downgrade

Hold

Reason

Jefferies lowered the firm's price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $23 and keeps a Hold rating on the shares as the firm expects the deal to be acquired by Alkermes (ALKS) to close in Q1 of 2026 after Lundbeck decided not to raise its November 14 offer. The firm now thinks the chances of a competing bid are unlikely and lowered its target to reflect Alkermes' November 18 offer to acquire Avadel for $22.50 per share, including $21 upfront and a $1.50 per share CVR.

Guggenheim

Buy

upgrade

$28 -> $43

2025-11-18

Reason

Guggenheim

Price Target

$28 -> $43

2025-11-18

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Centessa (CNTA) to $43 from $28 and keeps a Buy rating on the shares following the "promising" preliminary readout from the ORX750 CRYSTAL-1 Ph2a study as well as the "relatively underwhelming" results from alixorexton in NT2 that were reported by Alkermes (ALKS).

Truist

Buy

maintain

$50 -> $55

2025-11-17

Reason

Truist

Price Target

$50 -> $55

2025-11-17

maintain

Buy

Reason

Truist raised the firm's price target on Alkermes (ALKS) to $55 from $50 and keeps a Buy rating on the shares. Positive Vibrance-2 results materially de-risk the alixorexton program, supporting a higher probability of success and stronger estimates, the analyst tells investors in a research note. Cross-trial comparisons show alixorexton outperforming oveporexton in NT2, and the added split-dosing regimen in Phase 3 could further enhance efficacy, with Takeda (TAK) management viewing the program as credible competitive pressure.

Deutsche Bank

David Hoang

Buy

downgrade

$55 -> $45

2025-11-13

Reason

Deutsche Bank

David Hoang

Price Target

$55 -> $45

2025-11-13

downgrade

Buy

Reason

Deutsche Bank analyst David Hoang lowered the firm's price target on Alkermes to $45 from $55 and keeps a Buy rating on the shares. The company announced positive topline data from its Phase 2 VIBRANCE-2 trial of alixorexton in narcolepsy type 2, but results came in below the high expectations needed for the drug to be a "clear best-in-class therapy," the analyst tells investors in a research note. The firm believes the shares dropped yesterday on a perceived less competitive commercial profile for alixorexton versus peers.

Truist

Joon Lee

Buy

maintain

$50

2025-11-12

Reason

Truist

Joon Lee

Price Target

$50

2025-11-12

maintain

Buy

Reason

Truist analyst Joon Lee says that while Alkermes announced the dual endpoints were met in the Vibrance-2 dose-ranging Phase 2 study evaluating alixorexton in patients with narcolepsy type 2, the "details are scant." Truist is "comforted" that 95% of patients chose to enter the optional five-week open-label extension, which it believes speaks to a good benefit/risk ratio. The firm has a Buy rating on Alkermes with a $50 price target. The stock in morning trading is down 12%, or $3.94, to $29.88.

Evercore ISI

Outperform

maintain

$30.47

2025-11-12

Reason

Evercore ISI

Price Target

$30.47

2025-11-12

maintain

Outperform

Reason

Evercore ISI said the firm disagrees with the Street reaction on Alkermes (ALKS), adding that the "Street has had a confused reaction to all the new data out of Alkermes and Centessa recently." While the Street thinks the company missed the 20 minute MWT within the arm or greater than 10 minute MWT bar versus placebo, the firm contends "they didn't" and added that Alkermes avoided the "disaster scenario" of failing in narcolepsy type 2 like Takeda's (TAK) TAK-861. The firm, which thinks the Street is "grossly underestimating the clinician interest in this category for narcolepsy," has an Outperform rating on Alkermes shares, which are down $3.34, or 10% to $30.47 in morning trading.

Valuation Metrics

The current forward P/E ratio for Alkermes Plc (ALKS.O) is 13.98, compared to its 5-year average forward P/E of 94.95. For a more detailed relative valuation and DCF analysis to assess Alkermes Plc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

94.95

Current PE

13.98

Overvalued PE

245.12

Undervalued PE

-55.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

6.42

Current EV/EBITDA

9.76

Overvalued EV/EBITDA

78.22

Undervalued EV/EBITDA

-65.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.59

Current PS

2.72

Overvalued PS

4.43

Undervalued PS

2.76

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALKS News & Events

Events Timeline

No data

News

9.0

01-06NASDAQ.COM

Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton in Treating Narcolepsy Type 1

9.0

01-06Newsfilter

Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton in Treating Narcolepsy Type 1

8.5

2025-12-12PRnewswire

Avadel Pharmaceuticals to be Sold to Alkermes for $18.50 per Share

People Also Watch

Frequently Asked Questions

What is Alkermes Plc (ALKS) stock price today?

The current price of ALKS is 29.66 USD — it has increased 0.2 % in the last trading day.

What is Alkermes Plc (ALKS)'s business?

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

What is the price predicton of ALKS Stock?

What is Alkermes Plc (ALKS)'s revenue for the last quarter?

Alkermes Plc revenue for the last quarter amounts to 394.19M USD, increased 4.24 % YoY.

What is Alkermes Plc (ALKS)'s earnings per share (EPS) for the last quarter?

Alkermes Plc. EPS for the last quarter amounts to 0.49 USD, decreased -10.91 % YoY.

What changes have occurred in the market's expectations for Alkermes Plc (ALKS)'s fundamentals?

How many employees does Alkermes Plc (ALKS). have?

Alkermes Plc (ALKS) has 1800 emplpoyees as of January 10 2026.

What is Alkermes Plc (ALKS) market cap?

Today ALKS has the market capitalization of 4.90B USD.